Arvinas, Inc.
ARVN · NASDAQ
Market closed$8.01$-0.020000 (-0.25%)After hours $8.01 · 0.00%
Key statistics
Previous close$8.03
Open$7.94
Day high$8.18
Day low$7.90
52-week high$14.51
52-week low$6.06
Market cap516.81M
Volume494.56K
Average volume820.05K
P/E ratio-2.41
Forward P/E—
EPS-3.32
Dividend yield0.00%
Market context
Why it moved
Arvinas (ARVN) edged lower after Wall Street Zen downgraded the stock to "Strong Sell," adding negative sentiment pressure on top of the company's recent revenue miss and year-over-year sales decline.
What is happening
Recent company-specific developments and publisher coverage.
The Globe and Mail · June 23, 2026Arvinas Announces Chief Medical Officer Leadership TransitionTradingView · June 5, 2026Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial DataStock Titan · June 4, 2026Arvinas joins Michael J. Fox effort to develop new Parkinson's therapiesReuters · May 12, 2026Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drugBioPharma Dive · May 12, 2026Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugGlobeNewswire · May 12, 2026Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate UpdateInvesting.com · May 12, 2026Arvinas stock gains after Rigel deal for VEPPANU rightsThe Clinical Trial Vanguard · May 5, 2026FDA Approves Arvinas’ Vepdegestrant for ESR1-Mutant Breast Cancer Mt Newswire · June 16, 2026Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu Benzinga · June 3, 2026Stephens & Co. Reiterates Overweight on Arvinas, Maintains $18 Price Target Benzinga · June 2, 2026Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028 Benzinga · June 1, 2026Full Transcript: Arvinas Q1 2026 Earnings Call Mt Newswire · May 14, 2026BofA Securities Raises Price Target on Arvinas to $16 From $14 Benzinga · May 13, 2026These Analysts Increase Their Forecasts On Arvinas After Q1 Results Benzinga · May 13, 2026Barclays Maintains Overweight on Arvinas, Raises Price Target to $20 Benzinga · May 13, 2026BTIG Maintains Buy on Arvinas, Raises Price Target to $18